首页> 外文期刊>Cancer biology & therapy >Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma
【24h】

Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma

机译:用于癌症相关成纤维细胞靶向人食管鳞状细胞癌中的成纤维细胞活化蛋白的光瘤疗法

获取原文
获取原文并翻译 | 示例
           

摘要

Cancer-associated fibroblasts (CAFs) are strongly implicated in tumor progression, including in the processes of tumorigenesis, invasion, and metastasis. The targeting of CAFs using various therapeutic approaches is a novel treatment strategy; however, the efficacy of such therapies remains limited. Recently, near-infrared photoimmunotherapy (NIR-PIT), which is a novel targeted therapy employing a cell-specific mAb conjugated to a photosensitizer, has been introduced as a new type of phototherapy. In this study, we have developed a novel NIR-PIT technique to target CAFs, by focusing on fibroblast activation protein (FAP), and we evaluate the treatment efficacy in vitro and in vivo. Esophageal carcinoma cells exhibited enhanced activation of fibroblasts, with FAP over-expressed in the cytoplasm and on the cell surface. FAP-IR700-mediated PIT showed induced rapid cell death specifically for those cells in vitro and in vivo, without adverse effects. This novel therapy for CAFs, designed as local control phototherapy, was safe and showed a promising inhibitory effect on FAP(+) CAFs. PIT targeting CAFs via the specific marker FAP may be a therapeutic option for CAFs in the tumor microenvironment in the future.
机译:癌症相关的成纤维细胞(CAFS)在肿瘤进展中强烈地意义,包括在肿瘤发生,侵袭和转移过程中。使用各种治疗方法的CAFS的靶向是一种新的治疗策略;然而,这种疗法的功效仍然有限。最近,已经引入了近红外光疗法(NIR-PIT),其是使用与光敏剂缀合的细胞特异性MAb的新型靶向治疗,作为一种新型的光疗法。在这项研究中,通过专注于成纤维细胞活化蛋白(FAP),我们已经开发了一种新的先进坑技术来靶向CAFS,并且我们在体外和体内评估治疗效果。食管癌细胞表现出增强的成纤维细胞的激活,FAP在细胞质和细胞表面上呈上表达。 FAP-IR700介导的坑显示出在体外和体内的那些细胞的诱发快速细胞死亡,而没有不良反应。这种新的CAFS的疗法,设计为局部控制光疗法,是安全的,并且对FAP(+)CAFS表现出有希望的抑制作用。通过特异性标记FAP靶向CAFS可能是未来肿瘤微环境中的CAF的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号